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Abstract
We have compared a multiplexed bead-based assay (BBA) with an enzyme immunoassay (EIA) and immunoﬂuorescence assay (IFA) for
the assessment of the Epstein–Barr virus (EBV) serostatus. Three hundred and ninety-three sera, classiﬁed according to IFA results as
seronegative (n = 100), acute infection (n = 100), past infection (n = 100) and indeterminate (n = 93), were tested by BBA and EIA.
Overall, the three methods gave similar results with a relatively high (75.2%) concordance with the consensus interpretation of the
serostatus. The most signiﬁcant discordances were: (i) 58 samples had uninterpretable results for BBA, in majority due to the detection
of non-antigen speciﬁc antibody binding by control beads. (ii) almost half the samples positive for anti-Epstein–Barr nuclear antigen
(EBNA) IgG by BBA or EIA were negative by IFA. Among the latter, only a minority had a history of immunocompromise or treatment,
or detectable anti-early antigen antibody. This discrepancy probably reﬂects a poor sensitivity of IFA for anti-EBNA IgG detection. EIA
and BBA had a similar performance and had substantial practical advantages over IFA with respect to testing for EBV serostatus.
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Introduction
Epstein–Barr virus (EBV) is a gamma-herpesvirus that trans-
mits readily in humans, mostly by the oral route, infecting
more than 95% of the population worldwide [1]. After a pri-
mary infection, either asymptomatic or manifesting as an
infectious mononucleosis and characterized by viral replica-
tion in the oropharynx and in B lymphocytes, EBV-speciﬁc T
cells responses curtail viral replication. The virus DNA then
persists as an episomal DNA genome in memory B lympho-
cytes, with a very minimal gene expression, described as
a latent infection. Latent infection is related to lymphopro-
liferative and other malignant diseases in a complex manner
[2].
The diagnosis of the various stages of EBV infection and of
EBV-related malignant conditions is partly based on the
detection of different classes of antibodies speciﬁc for vari-
ous EBV antigens [the lytic viral capsid antigens (VCAs), the
latency-associated Epstein–Barr nuclear antigens (EBNAs)
and the replicative early antigens (EAs)] [3]. Multiplexed
assays offer the opportunity to assess antibody responses to
a panel of antigens in a single, specimen-sparing assay, with
reduced time requirements. We therefore compared the
diagnostic performance of the Athena Multi-Lyte multi-
plexed bead-based assay (BBA) for the detection of EBV-
speciﬁc antibodies with the monoplexed immunoﬂuorescence
assay (IFA) and enzyme immunoassay (EIA).
Materials and Methods
Patient samples
A total of 393 serum samples received in the serology labo-
ratory of the Institute of Microbiology, Centre Hospitalier
Universitaire Vaudois, for EBV testing by IFA between 1998
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and 2005 were included in the study. The sample population
included adult and paediatric specimens and a mix of speci-
mens from immunocompromised (e.g. solid organ transplant)
patients and those suspected of acute or latent EBV
infection.
The serum samples were classiﬁed into ﬁve groups
according to their IFA serostatus pattern: (i) 100 non-
infected (seronegative, anti-VCA IgM), anti-VCA IgG) and
anti-EBNA IgG–); (ii) 100 with acute infection (anti-VCA
IgM+, anti-VCA IgG+/) and anti-EBNA IgG–, only 94 of
which were available for analysis by multiplexed BBA); (iii)
100 with past infection (anti-VCA IgM), anti-VCA IgG+ and
anti-EBNA IgG+); (iv) 70 with type I indeterminate pattern,
possibly immunocompromised patients who had lost or not
developed responses against EBNAs or, rarely, acute
infection in the absence of anti-VCA IgM (anti-VCA IgM),
anti-VCA IgG+ and anti-EBNA IgG–); (v) 23 with type II
indeterminate pattern, possibly sub-acute infection or reacti-
vation (anti-VCA IgM+, anti-VCA IgG+ and anti-EBNA IgG+).
The samples had been stored in the temperature range )20
to )40C from the time of IFA testing and were centrifuged
for 5 min at 8000 g to remove protein aggregates after
thawing before testing by multiplexed BBA and EIA.
EBV-speciﬁc antibody testing
For each serum, the antibodies assayed were: anti-VCA IgM,
anti-VCA IgG and anti-EBNA IgG. The anti-EA IgG was
tested only in the BBA.
The serum samples had initially been analyzed by IFA
(Meriﬂuor), anti-EBV IgM and IgG IFA/IFT (Meridian Biosci-
ence, Cincinnati, OH, USA) and anti-EBNA ACIF (Focus
Technologies, Herndon, VA, USA), in accordance with the
manufacturers’ instructions [4]. Sixty microliters of serum
were used to analyse the three antibodies. HR1 cells
expressing the VCA antigen were used in the anti-VCA IgG
and IgM test kit [3,4]. According to the manufacturer, the
antigen used in the anti-EBNA IgG kit comprises ‘lymphoid
cells chosen for their selective production of EBNA antigen’.
Anti-VCA IgM was tested at a single 1 : 10 dilution in IFA
and samples were arbitrarily assigned a 1 : 5 titre if negative
and 1 : 20 if positive.
The samples were then analyzed by EIA (Novitec EBV-
EIA; Genbio, San Diego, CA, USA) and BBAs were per-
formed on a Luminex 100 reader (Athena Multi-Lyte EBV
IgG and IgM; Zeus Scientiﬁc, Raritan, NJ, USA), in accor-
dance with the manufacturer’s instructions. In the EIA, 10 lL
of serum were diluted and used to analyse the three
antibodies for each sample. The VCA antigen comprised
afﬁnity-puriﬁed gp125 VCA from a glycine extract of lysates
of EBV-infected cells (IgG and IgM) in EIA and BBA, whereas
the EBNA antigen was a recombinant EBNA-1 expressed in
a baculovirus system for EIA and expressed in Escherichia coli
for BBA. In the BBA, 10 lL serum were used for the three
IgG assays and 10 lL were used for the IgM test. The BBA
has built-in controls that assess the binding of antibodies to
beads not coated with antigen (nonspeciﬁc coating; NSC), to
minimize the false positive results.
Rheumatoid factor
To test the effect of rheumatoid factor on the results of
anti-VCA IgM by BBA, 46 prospective routine sera that gave
an NSC alarm (see above) for IgM were studied. Rheumatoid
factor was assayed by nephelometry using the N Latex RF
kit (Dade Behring, Eschborn, Germany). In addition, 10 lL of
serum were diluted in 200 lL of sample diluent containing
Fc-speciﬁc anti-IgG goat antiserum (Sample diluent 005M;
Zeus Scientiﬁc) and centrifuged for 5 min at 8000 g to
remove IgG. The supernatant was used in the BBA as
described above.
Serostatus interpretation
For each method, the dilution or index value was translated
into positive, negative or indeterminate qualitative results, in
accordance with the manufacturer’s instructions.
To compare the diagnostic interpretations of the three
methods, a consensus interpretation was established for each
antibody response using a majority rule. The consensus was
deﬁned as the majority interpretation if two out of three or
three out of three assays produced the same antibody inter-
pretation. There was therefore no deﬁned consensus when
all three results were different (or when one of the assays
produced an uninterpretable result; e.g. when the BBA gave
an undeﬁned result such as NSC and the two others gave
discordant results). The anti-EA antigen was available only
with the BBA and therefore was not included in this analysis.
The stages of the infection were deﬁned according to the
presence of the various antibodies as suggested by Hess [3]
(Table 1). Each serum specimen was attributed a serostatus
TABLE 1. Classiﬁcation of Epstein–Barr virus infection stage
according to serostatus pattern
VCA IgM VCA IgG EBNA IgG
Acute infection + +/) )
Past infection ) + +
Seronegative ) ) )
Indeterminate I ) + )
Indeterminate II + + +
Non plausible ) ) +
VCA, viral capsid antigen; EBNA, Epstein–Barr nuclear antigen.
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interpretation by each method and by consensus, and each
assay serostatus interpretations were compared with the
consensus interpretation.
Statistical analysis
The quantitative relationship between antibody titres and
indices was evaluated by linear regression using STATA 10
software (StataCorp, College Station, TX, USA) on log-trans-
formed values.
Ethical considerations
The present study was performed using samples left over
from clinically motivated EBV testing of patients who had
given consent with respect to their potential use for
research and development. This procedure was approved by
the local research ethics committee.
Results
For each antigen-speciﬁc antibody, the results of the three
methods were compared (Fig. 1).
Anti-VCA IgM
Fig. 1 (upper left) shows the relationship for anti-VCA IgM
assessed by EIA and IFA. There was generally a good qualita-
tive concordance (364/393; 93%) between these two tests
when classiﬁed as negative/indeterminate/positive. EIA
appeared somewhat less sensitive than IFA, with 21 discor-
dant samples (IFA positive/EIA negative). Because IFA testing
for anti-VCA IgM was run only qualitatively at a single 1 : 10
dilution, this precluded a quantitative comparison with EIA
and BBA indices.
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FIG. 1. For each antibody type, the three methods were compared with each other. The lower left (negative) and upper right (positive)
quadrants contain concordant data with the corresponding number of sera shown. The upper left and lower right quadrants show discor-
dant data. Numbers of data shown in the grey zone correspond to sera with minor discrepancies. Anti-viral capsid antigen IgM were deter-
mined at a single 1 : 10 dilution in the immunoﬂuorescence assay. Samples were arbitrarily assigned a 1 : 5 titre if negative and 1 : 20 if
positive. BBA, bead-based assay; EBNA, Epstein–Barr nuclear antigen; EIA, enzyme immunoassay; IF, immunoﬂuorescence; VCA, viral capsid
antigen.
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Fig. 1 (middle left) shows the relationships of anti-VCA
IgM results assessed by BBA and IFA. The smaller number of
data points is principally due to invalid NSC results in the
BBA. There was a good qualitative concordance (329/350;
94%) between these two tests. BBA had a sensitivity for
anti-VCA IgM intermediate between IFA and EIA, with only
ten discordant samples (IFA positive/BBA negative).
Finally, Fig. 1 (lower left) shows the qualitative concor-
dance between BBA and EIA indices (328/350; 94%) among
the 350 sera for which pairs of results were available. Both
EIA and BBA results were expressed as quantitative indices
and were highly correlated (r2 = 0.83).
With the BBA, 46 of 393 samples (among which 36 were
NSC for anti-VCA IgM and ten for anti-VCA and anti-EBNA
IgG) gave NSC results. The 46 selected sera had detectable
rheumatoid factor by nephelometry and gave NSC results
for anti-VCA IgM in the initial testing, but had no NSC
results when retested after absorption, with 42 of them
being negative and four being positive for anti-VCA IgM.
Anti-VCA IgG
Fig. 1 (upper central) shows the relationship between the
anti-VCA IgG results obtained with EIA and IFA. There was
good qualitative concordance (361/393; 92%) but no quanti-
tative correlation (r2 = 0.10). Fig. 1 (middle central) panel
shows the relationship between the anti-VCA IgG results
obtained with BBA and IFA. There was again a good qualita-
tive concordance (347/375; 93%) and a somewhat better
quantitative correlation (r2 = 0.37). Finally, Fig. 1 (lower cen-
tral) shows the good qualitative concordance between the
BBA and EIA results (340/375; 91%) but no quantitative cor-
relation (r2 = 0.08).
Anti-EBNA IgG
Fig. 1 (upper right) shows the relationship between the anti-
EBNA IgG results obtained with EIA and IFA. There was a
low qualitative concordance (300/393; 76%) compared to
anti-VCA IgM and anti-VCA IgG tests and again no obvious
quantitative correlation (r2 = 0.11). Fig. 1 (middle right)
shows the relationship between the anti-EBNA IgG results
obtained by BBA and IFA. There was a low qualitative con-
cordance (278/373; 75%) and again no obvious quantitative
correlation (r2 = 0.16). Finally, Fig. 1 (lower right) shows a
relatively high qualitative (330/373; 88%) and quantitative
(r2 = 0.44).concordance between the the BBA and EIA
results.
Comparison of serostatus interpretations
Table 2 shows the comparison between IFA and consensus
interpretations of the stage of infection. There were 286/387
(73.9%) concordant interpretations and 74/387 (19.1%) dis-
cordant ones, whereas 27/387 (7.0%) samples had no con-
sensus by the majority rule. This relatively low concordance
was mostly the result of infection classiﬁed as indeterminate
by IFA with the anti-VCA IgG+ and anti-EBNA IgG) serosta-
tus pattern and as past infection by the consensus (due to
EIA and BBA positive anti-EBNA IgG results). This was the
case for 56 serum samples.
Table 3 shows the comparison between EIA interpreta-
tions and the consensus interpretations. There was a better
concordance (329/387; 85%) with only 18/387 (4.7%) discor-
dant interpretations. For 40 samples (10.3%), no comparison
of interpretations could be made because consensus could
not be reached or EIA serostatus was indeterminate (grey
zone result). The relatively low sensitivity of EIA and BBA
for anti-VCA IgM resulted in a reduced number of acute
infection interpretations (82, 67 and 72 cases with IFA, EIA
and BBA, respectively).
TABLE 2. Comparison of immunoﬂuorescence assay and
consensus interpretations
Consensus
Immunoﬂuorescence assay
Non-
infected
Acute
infection
Past
infection Indeterminate Total
Non-infected 85 – – – 85
Acute infection – 82 – 3 85
Past infection 5 – 96 56 157
Indeterminate 3 2 3 23 31
Non plausible 2 – – – 2
No consensus 5 10 1 11 27
Total 100 94 100 93 387
TABLE 3. Comparison of enzyme immunoassay and consensus interpretations
Consensus
Enzyme immunoassay
Non-infected Acute infection Past infection Indeterminate Non plausible Grey zone Total
Non-infected 80 – – 3 – 2 85
Acute infection – 67 – 9 – 9 85
Past infection – – 154 2 – 1 157
Indeterminate – – 3 27 – 1 31
Non plausible – – 1 – 1 – 2
No consensus – – 6 3 – 18 27
Total 80 67 164 44 1 31 387
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Table 4 shows the comparison of consensus interpreta-
tions of the BBA. There were 291/387 (75.2%) concordant
interpretations but only 28/387 (7.2%) discordant ones. For
64 samples (17.6%), no comparison could be made because
consensus could not be reached, or because of invalid NSC
results in the BBA.
Because there was a substantial discrepancy between IFA
and the other two methods for the anti-EBNA IgG results,
we reviewed the clinical charts of the 70 patients with the
anti-VCA IgG+, IgM), anti-EBNA IgG) serostatus pattern
and found that only 28 of these patients had evidence of
immunosuppressive conditions or treatment that may explain
a negative anti-EBNA IgG result in a patient with past infec-
tion. Another cause of discrepancy may be young age. The
42 patients without immunosuppressive conditions were
aged from 1 month to 87 years (median 29 years) with a
25th percentile at 19 years. We also reviewed the BBA anti-
EA IgG results of these 70 patients). Fifty were anti-EA IgG-
negative, ten were positive, seven were in the grey zone and
three were invalid (two due to NSC), without any obvious
relationship with the patient’s immune status.
IFA is acknowledged as the reference method in EBV
serology. We therefore compared the IFA results with those
of the newer methods (EIA and BBA) (Tables 5 and 6). The
major difference compared with Tables 3 and 4 is in the clas-
siﬁcation of past infections (as deﬁned by EIA and BBA) as
indeterminate infections by IFA, again indicating a relatively
low sensitivity of our IFA for anti-EBNA IgG.
Discussion
In the present study, we compared the diagnostic perfor-
mance of a recently developed multiplexed BBA that allows
the determination of antibody responses to several antigens
in the same reaction. In the absence of a gold standard to
ascertain the status of EBV infection, the diagnostic perfor-
mance of this assay was assessed by comparison with the
TABLE 4. Comparison of bead-based assay and consensus interpretations
Consensus
Bead-based assay
Non-infected Acute infection Past infection Indeterminate Non plausible Grey zone NSC Total
Non-infected 67 3 1 6 2 1 5 85
Acute infection – 72 – 4 – – 9 85
Past infection – – 135 2 2 – 18 157
Indeterminate – 1 5 17 – 3 5 31
Non plausible – – 2 – – – – 2
No consensus – 1 7 7 – 2 10 27
Total 67 77 150 36 4 6 47 387
NSC, nonspeciﬁc coating.
TABLE 5. Comparison of enzyme and immunoﬂuorescence assay interpretations
Immunoﬂuorescence
assay
Enzyme immunoassay
Non-infected Acute infection Past infection Indeterminate Non plausible Grey zone Total
Non-infected 80 – 6 6 1 7 100
Acute infection – 65 2 12 – 15 94
Past infection – – 93 5 – 2 100
Indeterminate – 2 63 21 – 7 93
Total 80 67 164 44 1 31 387
TABLE 6. Comparison of bead-based and immunoﬂuorescence assay interpretations
Immunoﬂuorescence
assay
Bead-based assay
Non-infected Acute infection Past infection Indeterminate Non plausible Grey zone NSC Total
Non-infected 67 3 12 7 2 2 7 100
Acute infection – 69 – 10 – 1 14 94
Past infection – – 81 6 1 – 12 100
Indeterminate – 5 57 13 1 3 14 93
Total 67 77 150 36 4 6 47 387
NSC, nonspeciﬁc coating.
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reference methods and with a consensus of the results for
all three methods determined by a majority rule. Compared
with previous studies assessing the diagnostic performance of
similar assays, the present study had more samples that were
representative of each serostatus pattern determined by IFA
[5–7]. It also had immunoﬂuorescence data available for all
samples, and not just for EIA/BBA discordant results as was
the case in the study by Binnicker et al. [8].
Overall, we observed a good qualitative correlation
between the three methods for detecting anti-VCA IgG and
IgM antibodies. Of note, the serum samples had been frozen
and stored for several years before testing by EIA and BBA,
although we did not observe a reduced sensitivity for these
tests compared with IFA that had been performed on fresh
unfrozen sera. Thus, discrepancies cannot be attributed to
antibody loss as a result of storage. Another potential source
for discrepancies could be the use of different antigens in
these tests. Both EIA and BBA used recombinant gp125
VCA, whereas the IFA assay used HR1 cells that express this
antigen and other lytic antigens [9].
Compared with IFA and EIA, BBA had a slightly reduced
sensitivity for the detection of anti-VCA IgM, resulting in in
less frequent interpretations of acute infection.
By contrast, we observed a clearly reduced sensitivity of
IFA compared to the two other methods for the detection
of anti-EBNA antibodies. Although the two latter tests use
recombinant EBNA-1 as antigens, IFA was performed using
(in accordance with the manufacturer’s instructions) ‘lym-
phoid cells chosen for their selective production of EBNA
antigens’. We could not obtain more details, although it is
likely that these are latently EBV-infected cells that may
express more latent antigens than just EBNA-1. If anything,
this should result in IFA being more sensitive than the other
assays. Second, anti-EBNA-1 IgG antibodies have been
decribed as appearing later than other anti-EBNA antibodies
but with life long persistence [3]. Thus, if the cells used for
IFA testing expressed little EBNA-1, this would account for
the apparent lack of sensitivity of IFA in patients with a pat-
tern otherwise reﬂecting past infection (anti-VCA IgG+, anti-
VCA IgM)).
Anti-EBNA IgG antibodies have been reported to disap-
pear during EBV reactivation in immunocompromised
patients [3,10]. However, among patients with discordant
anti-EBNA IgG results (in the setting of positive anti-VCA IgG
and negative IgM), only a minority had a history of immuno-
suppressive conditions, and even less detectable anti-EA anti-
bodies that are a marker for EBV reactivation [3]. Therefore,
it is likely that, in the majority of discordant results where
anti-EBNA antibodies were detected by EIA and/or BBA,
these were true positives in patients with past infection.
Indeterminate (type I) results might also occasionally
occur in acute infection in the absence, or after rapid disap-
pearance, of anti-VCA IgM in paediatric patients. However,
only a minority of our patients were children. We also
included type II indeterminate samples (anti-VCA IgM+, anti-
VCA IgG+ and anti-EBNA IgG+) in our study. In both types
of indeterminate results, the assessment of anti-VCA IgG
avidity may be helpful in deciding the stage of infection [3].
Finally, we cannot exclude the possibility that these discrep-
ancies are consistant false positive anti-EBNA IgG results
with EIA and BBA as a result of long-term freezing.
Titres of anti-VCA IgG assessed by EIA have been
reported to carry useful information as markers for EBV
reactivation and correlate with EBV DNA load in the blood
in various EBV-related malignancies, such as Hodgkin’s lym-
phoma [11] or nasopharyngeal carcinoma [12]. It is impor-
tant in this respect to note the poor quantitative correlation
between BBA and EIA indices and immunoﬂuorescence
titres. This suggests that anti-VCA IgG results should not be
interpreted quantitatively, irrespective of the method used.
Although our quantitative discrepancies between BBA and
IFA or EIA and IFA may be ascribed to differences in anti-
gens, it is more difﬁcult to explain the discrepancy between
BBA and EIA because both are based on the same antigen.
This lack of correlation may in part be the result of diluted
samples not being run when samples gave out of range sig-
nals, which occurred in a substantial number of samples, as
can be seen by the funnelling of dots in the upper right cor-
ner of the graph in Fig. 1 (BBA vs. EIA anti-VCA IgG; lower
central graph).
In any case, the diagnosis of nasopharyngeal carcinoma
should include testing for primarily IgA directed against vari-
ous EBV antigens by IFA and BBA [13].
The concordance of BBA appeared lower than the con-
cordance of EIA with the consensus, although this was
related to the implementation of an internal control in the
BBA that detected NSC in samples that may otherwise give
a false positive result. At the time of the study, the cut-off
values for NSC were relatively low, leading to the designa-
tion of 58 results as invalid, of which 47 were the result of
NSC. Forty-four of those sera were available for retesting
with a new version of the kit (reset threshold and new wash
buffer). Of those, none tested NSC for IgG and 12 of 44
remained NSC for IgM. In addition, this residual problem
could be solved by the use of an IgG absorption step before
IgM testing as demonstrated in prospective samples.
In conclusion, BBA compared favourably with the refer-
ence IFA and produced similar resuts to the EIA methods.
Both BBA and EIA offer a substantial saving in time as well
as sample size (10 and 20 lL, respectively, vs. 60 lL for IFA)
CMI Devanthe´ry and Meylan Multiplexed bead-based assay in EBV serology 1781
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1776–1782
and do not require training in ﬂuorescence microscopy.
However, BBA requires only two assays compared to one
assay per antibody speciﬁcity for EIA and IFA. Finally, the
BBA requires a costly ﬂow cytometry reader.
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